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THE PAST
The Birth
Although there is abundant evidence that the critical im-
portance of the heart was appreciated during prehistory as
well as in ancient times, its function was first defined by
William Harvey, a British physician. The inspiration for his
seminal discovery, considered by historians as one of the
scientific triumphs of the Renaissance, came from the
school of great anatomists of the University of Padua, where
Harvey studied medicine and from which he graduated four
centuries ago, in 1603. In his earth-shaking publication in
1628, De Motu Cordis, Harvey stated: “It has been shown by
reason and experiment that by the beat of the ventricles
blood flows through the lungs and it is pumped to the whole
body. There it passes through pores in the flesh into the
veins through which it returns from the periphery…finally
coming to the vena cava and right auricle…It must then be
concluded that the blood in the animal body moves around
in a circle continuously, and that the action or function of
the heart is to accomplish this by pumping. This is the only
reason for the motion and beat of the heart” (1).
Commencing 275 years after Harvey’s publication, the
20th century witnessed a series of grand achievements in
cardiology that have been critical to the development of the
specialty. Ten of the most notable are discussed.
Ten Great Achievements of the 20th Century
Electrocardiography. Although diseases of the heart were
recognized well before the 20th century, and whereas great
physicians such as William Osler, James Hope, Austin
Flint, and Pierre Potain wrote extensively and perceptively
about physical examination of the heart and cardiovascular
disease, the birth of modern cardiology can be dated to one
century ago, when Willem Einthoven (Fig. 1A), a professor
of physiology in the small Dutch town of Leiden, first
recorded a human electrocardiogram and gave birth to a
new specialty. Einthoven devised the first string galvanom-
eter to record the electrical activity of the heart (2). His
work was built on the background provided by the German
physiologists von Koelliker and Muller (3) and the British
physiologist Augustus Waller (4). Einthoven was appropri-
ately rewarded with a Nobel Prize in medicine. Figure 1B
shows a reproduction of one of the first human electrocar-
diograms recorded with a string galvanometer. Einthoven
himself described various arrhythmias, including bigeminy,
atrial flutter and fibrillation, and “P mitrale,” as well as left
and right ventricular hypertrophy. Soon others utilized
electrocardiography to detect myocardial ischemia and in-
farction. Indeed, the electrocardiogram became so impor-
tant that in a few years cardiologists actually became defined
as physicians who could interpret electrocardiograms.
Cardiac catheterization. The noted 19th-century French
physiologist Claude Bernard catheterized and measured
pressures in the various cardiac chambers and great vessels
of the animal heart (5). The first catheterization of the living
human heart was performed by a young surgeon, Werner
Forssman (Fig. 2A), (on himself!) in 1929 in Eberswald,
Germany. Forssman’s goal was to find a safe way to inject
drugs and contrast material into the right atrium for cardiac
resuscitation (6). In 1941, Andre Cournand (Fig. 2B) and
Dickinson Richards (Fig. 2C) at Columbia University and
Bellevue Hospital in New York began the systematic explo-
ration of normal and abnormal hemodynamics (7,8). They
recorded intracardiac pressures and cardiac output in normal
subjects and in patients with many forms of congenital and
acquired heart disease. These investigators established car-
diac catheterization as the basis for defining normal and
disordered function of the cardiac pump and as a premier
diagnostic technique in cardiology. Forssman, Cournand,
and Richards were also awarded the Nobel Prize.
Cardiac catheterization opened the way for the study of
the mechanical function of the heart in a manner analogous
to what electrocardiography had done for its electrical
function a half-century earlier. Indeed, by the late 1950s, in
what was the dawn of subspecialization, many cardiologists
were already beginning to concentrate on one or the other of
these two important approaches and, accordingly, were
dubbed “electricians” or “plumbers.”
Coronary angiography. Cardiac catheterization paved the
way for coronary arteriography, which was first performed
by Mason Sones (Fig. 3A) at the Cleveland Clinic in 1958
(9). Coronary arteriography, when combined with left
ventriculography, led to the diagnosis and then the elucida-
tion of the natural history of coronary artery disease. This
technique made possible coronary revascularization, first
surgical and then percutaneous.
Cardiovascular surgery. Although there were a number of
early scattered attempts to operate on the human heart,
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modern cardiovascular surgery was first applied systemati-
cally in 1938, when Robert Gross (Fig. 2D) at Harvard and
Boston’s Children’s Hospital successfully closed a patent
ductus arteriosus (10). In 1953, John Gibbon (Fig. 2E) at
Thomas Jefferson Hospital in Philadelphia performed the
first open-heart operation using cardiopulmonary bypass
when he successfully closed an atrial septal defect in an
18-year-old girl (11). The development, successful applica-
tion, and refinement of open-heart surgery required the
close collaboration of surgeons, engineers, cardiologists,
anesthesiologists, and experts in blood coagulation. The
development of the heart-lung machine also appears to have
been among the first of many important successful
academic-industrial collaborations in cardiology, as Gib-
bon’s design led to the construction of the heart-lung
machine by IBM engineers.
Invasive cardiology. Building on the work of two pioneers
in radiology, Charles Dotter and Melvin Judkins, Andreas
Gruentzig (Fig. 3B), who was trained in cardiology, periph-
eral vascular disease, and radiology, burst on the world of
cardiology in 1977 (5,12,13). By developing percutaneous
transluminal coronary angioplasty, in one bold stroke he
established a new subspecialty: interventional cardiology.
Gruentzig expanded the use of the cardiac catheter, until
then a diagnostic tool, into a powerful therapeutic device.
Balloon angioplasty was followed by stenting with bare
metal stents, which are now being replaced by drug-eluting
stents. In addition to coronary stenosis, almost any abnor-
mal obstruction in the heart and circulation can now be
successfully opened, and many abnormal openings can be
successfully closed using catheter-based techniques.
The coronary care unit. Before 1961, patients with acute
myocardial infarction who were fortunate enough to reach
the hospital were treated largely with benign neglect. They
were sedated and placed at bed rest, as far removed
physically as possible from the noise and excitement of the
nurses’ station. The early mortality of acute myocardial
infarction patients who reached the hospital exceeded 30%.
In 1961, Desmond Julian (Fig. 3C), then a registrar in
cardiology at the Royal Infirmary in Edinburgh, Scotland,
articulated the concept of the coronary care unit (14). This
important development rested on four pillars: 1) continuous
electrocardiographic monitoring with arrhythmia alarms; 2)
cardiopulmonary resuscitation with external ventricular de-
fibrillation; 3) the clustering of myocardial infarction pa-
tients in a discrete unit of the hospital where skilled
personnel, drugs, and equipment were available; and 4)
perhaps most important, a change in policy that permitted,
indeed mandated, trained nurses to initiate resuscitation.
With institution of coronary care units, the in-hospital
mortality of acute myocardial infarction was immediately
reduced in half, and in a little more than a year these units
had spread across the world like wildfire and soon became a
requirement for hospital accreditation.
Cardiovascular drugs. In the 1960s, while working for the
British pharmaceutical company Imperial Chemical Indus-
tries, James Black (Fig. 4A) developed beta-blockers and
was later honored for this and other discoveries with the
Nobel Prize (15). These remarkable agents have benefited
patients with acute and chronic myocardial ischemia, heart
failure, a variety of arrhythmias, and hypertension. The first
angiotensin-converting enzyme inhibitor, captopril, was
isolated in the 1970s by Cushman (Fig. 4B) and Ondetti
(Fig. 4C), working at the Squibb (now Bristol Myers
Squibb) laboratories. Angiotensin-converting enzyme in-
hibitors have become cornerstones in the management of
heart failure and hypertension (16). The first HMG-CoA
reductase inhibitor (statin) was isolated by Akira Endo (Fig.
4D) of Sankyo Pharmaceuticals in 1976 (17), and was built
on the Nobel Prize-winning work on the low density
lipoprotein cholesterol pathway by Brown and Goldstein
(18). Statins reduce substantially the incidence of coronary
events, and prolong life both in subjects with and without
hypercholesterolemia. Taken together, beta-blockers,
angiotensin-converting enzyme inhibitors, and statins have
prolonged and improved the lives of tens, perhaps hundreds,
of millions of patients worldwide.
Figure 1. (A) Willem Einthoven. (B) A human electrocardiogram (2).
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Figure 2. (A) Werner Forssman; (B) Andre F. Cournand; (C) Dickinson W. Richards; (D) Robert E. Gross; (E) John H. Gibbon, Jr.
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Preventive cardiology. In 1944, Dr. Paul Dudley White
(Fig. 5A), at Harvard and the Massachusetts General
Hospital, often referred to as the father of American
cardiology, pioneered the concept of cardiovascular preven-
tion (19). Stimulated by White’s influential advocacy, in
1948 the National Heart Institute (now the National Heart,
Lung, and Blood Institute) established the Framingham Heart
Study, the first prospective population-based cohort study that
focused on heart disease. The study investigators developed the
concept of coronary risk factors, and by 1961 in a now classic
paper by Kannel et al. (Fig. 5B) (20), they had identified
hypertension, smoking, and electrocardiographic evidence of
left ventricular hypertrophy as such risk factors. Based on these
(and other subsequently identified) risk factors, the primary
and secondary prevention of coronary artery disease has been
responsible for almost one-half of the dramatic 70% decline in
age-adjusted deaths from coronary artery disease that has
occurred since their publication.
Echocardiography. One of the most fruitful collaborations
in the history of cardiology was between Inge Edler, a
Swedish cardiologist, and Helmuth Hertz (Fig. 6), a Swed-
ish physicist. In 1952, they adapted for human use a sonar
device for detecting submarines in World War II and
recorded echoes from the walls of the heart of one of the
coinventors, “Hertz’ heart,” and thereby launched the field
of echocardiography (21). These investigators provided
continuous recordings of the movements of the heart walls
and of the normal and diseased mitral valve. The visualiza-
tion of the heart and great vessels by noninvasive imaging,
first by echocardiography and subsequently by a variety of
nuclear techniques, as well as by advanced radiologic tech-
niques (computed tomography and magnetic resonance
imaging) now makes many invasive diagnostic procedures
unnecessary. By permitting sequential testing, such imaging
allows the optimal timing of interventions and assessment of
the response to treatment. Noninvasive imaging represents
Figure 3. (A) F. Mason Sones, Jr.; (B) Andreas R Gruentzig; (C) Desmond G. Julian.
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an enormous advance both in the diagnosis of heart disease
and in the care of cardiac patients.
Pacemakers and internal defibrillators. Building on the
work of electrophysiologists in the first half of the 20th
century, in 1952 Paul Zoll (Fig. 5C), a cardiologist at
Harvard and Beth Israel Hospital, developed the first
external pacemaker (22) and, in 1959, Elmquist and Sen-
ning at the University of Zurich (23,24) reported on the first
successful use of an internal pacemaker. In 1970, Michel
Mirowski (Fig. 5D), an Israeli cardiologist with training in
electrical engineering working at Sinai Hospital in Balti-
more, invented the implanted cardioverter-defibrillator (25),
and a decade later reported on its successful clinical appli-
cation (26). A steady drumbeat of successful clinical trials
has greatly extended the indications for this important
device, both in the secondary and primary prevention of
sudden cardiac death (27).
Key Lessons From the Past
It should be noted that the achievements described here
have been selected from many others that also have had
major impacts on cardiology. Some of these are included in
a recent review by Mehta and Khan (28).
What can we learn when we step back and view these
spectacular achievements? At least three points are notable.
First is that these achievements did not develop de novo; they
were built on many decades of research, usually by basic
scientists and engineers, the unsung heroes of progress in
cardiology. Second, in almost every instance, these advances
came from interdisciplinary collaborations, such as between a
Figure 4. (A) James W. Black; (B) David W. Cushman; (C) Miguel A. Ondetti; (D) Akira Endo.
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cardiologist and physicist in the case of echocardiography, or
between epidemiologists and cardiologists in the Framingham
Heart Study. Successful collaboration between academia and
industry has also been vital to many of these advances.
Examples are the first heart-lung machine and cardiac drugs, as
well as catheters and electrical devices. Third, these great
achievements are international triumphs; investigators in eight
countries on three continents are among those mentioned and
pictured here. Countless others from dozens of nations have
contributed importantly to contemporary cardiology.
THE PRESENT
As a result of the enormous achievements just enumerated,
and many others, cardiology is now a vibrant, robust
specialty of which we can be justifiably proud, and that is
providing enormous benefits to society. However, contem-
porary cardiology faces several major challenges.
Subspecialization. The growing technical complexities of
cardiologic diagnosis and treatment, and the necessity of
maintaining very high levels of skill in order to optimize patient
care, have led to increasing subspecialization. Contemporary
cardiology is composed of multiple subspecialties, many with
their own training requirements, professional societies, and
journals. In adult medical cardiology alone, there are subspe-
cialists in invasive cardiology, in noninvasive diagnosis, and
sub-subspecialists in each of the major imaging modalities.
There are electrophysiologists, subspecialists in extracardiac
vascular disease, hypertension, lipidology, care of patients with
acute coronary syndromes, and heart failure, as well as in
prevention and rehabilitation. Others are certain to follow.
Pediatric cardiology, cardiovascular surgery, and cardiovascular
radiology are now following the lead of adult cardiology and
are developing subspecialties of their own.
Undoubtedly, subspecialization has enormous benefits; it
Figure 5. (A) Paul D. White; (B) William B. Kannel; (C) Paul M. Zoll; (D) Michel Mirowski.
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leads to greater expertise and thereby greatly improves
patient care, teaching, and research. However, it also frag-
ments care. Subspecialists might be likened to virtuosi
playing different instruments in the orchestra. But one may
ask: where is the conductor—the physician who oversees
and integrates the care of the cardiac patient? Skilled
subspecialists can perform complicated procedures success-
fully and at relatively low risk, but may not always pay equal
attention to the more fundamental question of whether the
procedure should be performed in the first place.
The subspecialist approach tends to be most effective in
young patients with clearly defined diseases, for example,
the electrophysiologist diagnosing reentry tachycardia and
ablating the abnormal pathway in a young adult. However,
older patients often have more complex conditions that
involve disturbed structure and function of several compo-
nents of the cardiovascular system, and they usually have a
number of comorbid noncardiac conditions. The elderly, the
most rapidly growing segment of the population, require
more than expert subspecialists; their care requires a broad
multidisciplinary approach. There is a great scarcity of the
aforementioned integrators of cardiac care (the “conduc-
tors”) and there is insufficient reimbursement for their
important contributions to patient care. For example, it is
now possible for an experienced surgical team to perform
repeat coronary artery bypass grafting on an octogenarian
with diabetes, left ventricular and renal dysfunction, and
advanced multivessel native coronary artery and graft disease
at a risk that is acceptable to the patient and family.
Complex presurgical evaluation, including testing for the
viability of akinetic myocardium, is conducted routinely in
such patients. Although such a patient may have early
dementia, careful assessment of cognition is rarely carried
out, and the results of formal cognitive testing are rarely
considered in the decision whether to proceed with surgery.
Disease prevention. Despite the dazzling technical ad-
vances in cardiology, risk factor reduction and disease
prevention in the population are inadequate. Although cardi-
ologists now do quite well in this area, most patients with
cardiac disease or risk factors now, and in the foreseeable
future, will receive their cardiac and preventive care not from
cardiologists, but from primary care internists and family
practitioners. The latter usually know when aspirin, beta-
blockers, angiotensin-converting enzyme inhibitors, and statins
are indicated. But a disturbing fraction of patients who require
these life-prolonging medications are not prescribed them or
fail to take them. Individual cardiologists and cardiovascular
organizations such as this College must assume the lead in
correcting this unsatisfactory situation.
Costs of cardiac care. After decades of dire predictions, a
crisis in the payment for healthcare is now squarely upon us,
and the costs of care are spiraling out of control. The fruits
of our research, the newest diagnostic devices and therapeu-
tic strategies in cardiology, are prominent contributors to
the rapidly escalating costs. Further developments in cardi-
ology that are now in the wings might “break the bank.”
The solution to this vexing problem must not be left to
legislators or regulators. Instead, cardiac specialists them-
selves must develop diagnostic and therapeutic strategies
that are evidence based, as with the well-developed ACC/
AHA guidelines program (29), but they must also be more
mindful of limited resources.
Cardiology work force. Ten to 15 years ago armies of
well-paid consultants looked into their collective crystal
balls and prophesied that primary care physicians serving as
Figure 6. Helmuth Hertz (left) and Inge Edler (right) with the first
echocardiograph.
Figure 7. Heart failure hospitalizations. From: Heart Disease and Stroke
Statistics: 2003 Update. Dallas, TX: American Heart Association, 2003.
Figure 8. The near-term future of therapy for advanced heart failure. Art.
Ht.  artificial heart; BMSC  bone marrow stem cells; ICD  implantable
cardioverter-defibrillator; LVAD  left ventricular assist device.
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gatekeepers in a capitated system would become the model
for medical care in the U.S. This approach would reduce
costs by keeping patients away from specialists for as long as
possible and thereby reduce the need for specialists. Cardi-
ology training programs were downsized at the very time
that the needs for cardiologists were expanding. As a
consequence, there is now a critical and growing need for
well-trained cardiac specialists to apply the new advances in
a timely manner. This important issue, too, must now be
addressed by organized cardiology.
THE FUTURE
The near term (2003 to 2020). In the near term, until
approximately 2020, it is likely that there will be continuing
subspecialization in the pursuit of technical virtuosity and
clinical excellence. This situation will at first both aggravate
the escalation of costs and intensify the workforce shortage.
At the same time, preventive measures based on patient
characteristics, such as phenotypes, will expand. New phe-
notypic risk markers, of which the C-reactive protein may
be considered to be a prototype (30), will be helpful in this
regard. The prevalence of heart failure will grow. There will
be increasing application of pharmacogenomics.
Heart failure is the last great battleground in cardiology.
Figure 7 shows the ominous increase in the number of
annual discharges of heart failure patients from U.S. hospi-
tals. In the near-term future the management of heart
failure is likely to advance along three paths (Fig. 8). The
first will come from a great expansion and broadening of the
indications for electrical device therapy such as cardiac
resynchronization (31) and implanted cardiac cardioversion
and defibrillation (27). Mechanical assistance for long-term
management is improving steadily (32). Innovative efforts
are underway to coax the failing heart to recover following
the removal of a left ventricular assist device in so-called
“bridge to recovery” therapy (33). Cell therapy represents a
very promising approach. Two modes are now under active
investigation: the injection of cultured autologous myoblasts
(34) and the use of autologous bone marrow-derived stem
cells (35). For patients with acute severe heart failure,
mechanical ventricular assistance is likely to be employed as
bridging therapy while cell therapy regenerates the heart.
Cardiac xenotransplantation (36) might become a reality,
and this could change drastically the entire landscape of the
management of severe heart failure.
Pharmacogenomics represents the “low-hanging fruit” of
the genetics/genomics revolution. The goal of this emerging
field is to identify patients likely to exhibit adverse effects
and those most likely to respond well to specific drugs. One
example of how pharmacogenomics could influence cardi-
ologic practice is in the use of warfarin. The hepatic
microsomal enzyme CYP2C9 is required for the metabo-
lism of this anticoagulant. There are three variants of the
gene that encodes this enzyme (37): the so-called wild type
occurs in approximately 70% of the population and the
other two variants combined occur in the remainder. The
latter cause a defect in warfarin metabolism that is associ-
ated with markedly reduced requirements of maintenance
doses (38), a longer period until stable dosing is achieved,
and a more than doubling of the rate of serious bleeding,
even after stable dosing has been achieved at these lower
doses (39). Screening for these variants could improve
Figure 9. Effect of hormone replacement therapy (HRT) on high-density
lipoprotein cholesterol (HDL-C) by genotype. Modified from (41).
Figure 10. Adrenergic receptor variants in heart failure. Modified from (47). NE  norepinephrine.
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dosing and surveillance and greatly improve identification of
patients who do not tolerate warfarin and who would
therefore become prime candidates for the new, expensive
oral anticoagulants that will soon be available. Conversely,
and equally importantly, such screening could also identify
the many patients who are likely to tolerate the inexpensive
warfarin. Once commercialized, this genetic test, conducted
only once, could improve the care of the hundreds of
thousands of patients who require chronic anticoagulation,
and significantly reduce the cost of their care.
The adverse effects of hormone replacement therapy in
postmenopausal women has received enormous medical and
public attention since the publication of the results of the
Women’s Health Initiative (40). Vague recommendations are
made to physicians, and by them to tens of millions of women.
It is unsatisfactory to expect primary care physicians to analyze
and interpret the totality of evidence on this complex issue and
in the final analysis, ask every woman to decide this matter for
herself. The ability to raise high-density lipoprotein cholesterol
(HDL-C) concentration has been a major impetus for hor-
mone replacement therapy. However, HDL-C is not elevated
uniformly by hormone replacement therapy and the differences
in responses appear to be strongly influenced by the genetic
background of the woman. There are two variants of the gene
that encodes the estrogen receptor alpha, termed C and T.
Fifteen percent of women have the CC genotype, and with
hormone replacement therapy this subgroup showed a robust
26% increase in HDL-C (Fig. 9) (41). Epidemiologic consid-
erations suggest that such an elevation could reduce the
development of coronary events by half. On the other hand,
little change in HDL-C was seen in the 85% of women with
the other two genotypes (TT or CT). Therefore, the subgroup
of postmenopausal women with the CC genotype are logical
candidates for consideration of hormone replacement therapy.
Another genetic variant, the prothrombin 20210G-A vari-
ant, has been shown to be associated with elevated concentra-
tions of circulating prothrombin and an increased risk of
venous thrombosis (42). In hypertensive women with this
variant who receive hormone replacement therapy, the risk of
myocardial infarction was increased 11-fold (43)! Pharmaco-
genomics should lead to more rational use of these agents and
deal with what is now a vexing public health problem.
The long-term future (2020 and beyond). Prediction be-
yond 2020 is more problematic. However, it is very likely that
advances in genetics and genomics will allow the subclassifica-
tion of disease, which will lead to gene-informed therapy, that
is, “smart” therapy. Also, genetic identification of the future
development of risk factors will lead to gene-informed person-
alized prevention: “smart” prevention. Several examples illus-
trate these possible strategies. Alpha-adducin is a cytoskeletal
protein involved in cell signaling. A variant of the alpha-
adducin gene is present in about one-third of hypertensives,
and leads to excessive sodium re-absorption by distal renal
tubule cells. There is now considerable discussion about the
role of diuretics in the treatment of hypertension (44,45). Psaty
et al. (46) reported that in two-thirds of hypertensives with the
most common, so-called wild-type, genotype of the alpha-
adducin gene, diuretic treatment did not reduce the risk of
myocardial infarction or stroke. In the other third with the
variant genotype, diuretic treatment was associated with a
reduction of myocardial infarction or stroke by half. If this
work is confirmed, it could lead to the screening of hyperten-
sives for this variant in selecting antihypertensive therapy, an
example of gene-informed therapy. It might prove useful even
to screen normotensive subjects for this variant and to treat
them prophylactically with a salt-restricted diet or even a
diuretic, leading to gene-informed prevention.
Two synergistic variants for adrenergic receptors have been
described (47). A variant of the 2c-adrenergic receptor in-
creases norepinephrine release from sympathetic nerve end-
ings, whereas a variant of the 1-receptor increases the re-
sponse of myocytes to norepinephrine (Fig. 10). In African-
American subjects with both of these gene variants, the risk of
development of hypertension was increased more than 10-fold,
making these patients prime candidates for very early therapy
with an 2-adrenergic agonist and 1-blocker. Perhaps even
Figure 11. Prediction of the relative impact of interventions and prevention.
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prophylactic therapy in subjects with this combination of gene
variants but without heart failure might be considered.
Some early examples of how genetics will enhance risk
stratification for atherosclerosis are also available. The
presence of specific variants of the genes for connexin 37
(resulting in changes in endothelial gap junctions) in men
and in the genes for plasminogen activator inhibitor-1
(altered inhibition of fibrinolysis) and stromelysin-1 (asso-
ciated with altered matrix metabolism) in women are
associated with increased risk of myocardial infarction (48).
Variants of an ATP-binding cassette transporter gene
(ABCC-6) are associated with a more than four-fold
increase in premature coronary artery disease (49). On the
other hand, several gene variants (p22phx, associated with
vascular smooth muscle production of reactive O2 species
[48] and the toll-like receptor 4, associated with a dimin-
ished immune response [50]) are associated with reduced
risk of atherosclerosis. These early observations point the
way to gene informed prevention.
Intervention versus prevention. Figure 11 represents a
prediction of the future use and impact of interventional and
preventive cardiology. In the short-term future, until ap-
proximately 2020, many more useful interventions of all
types (drug-eluting stents, more effective electrical and
mechanical devices, cell therapy, perhaps xenotransplants)
will become available. This will be accompanied by a great
expansion of the population that can benefit from these
interventions: a large increase in the elderly, in persons at
high risk, including diabetics and the obese, and in those
who have had a previous intervention. Simultaneously, there
will be a greater focus on prevention, using progressively
greater refinements of markers of inflammation and of
plaque instability. However, the balance of these two
influences will favor intervention and the number of proce-
dures will continue to expand. Beyond 2020, interventions
are certain to continue to become more useful, and they will
continue to become simpler, more effective, and less expen-
sive. However, the application of genetics and genomics to
cardiovascular disease will tip the balance and the need for
intervention will decline, at first gradually, then rapidly.
CONCLUSIONS
The principal role of the cardiologist will change from recog-
nizing and managing established disease, as is the case today, to
interpreting and applying genetic information in prevention
and treatment in 2020 and beyond. The grand goal, of course,
is to eliminate cardiovascular disease as a major threat to long,
productive life. It is hoped this will be well underway by 2028,
the 400th anniversary of William Harvey’s discovery of the
circulation and the 125th anniversary of Willem Einthoven’s
development of the string galvanometer.
Reprint requests and correspondence: Dr. Eugene Braunwald,
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